Telix at ANZSNM Annual Scientific Meeting 2022
9 May 2022 – Corporate Spotlight | Telix supporting and participating in Australian and New Zealand Society of Nuclear Medicine Annual Scientific Meeting 2022
Telix is a title partner of the 52nd Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting (ASM) being held this week in Brisbane, Queensland, 13-15 May.
In addition, it is our pleasure to once again support the Pre-Conference Symposium, this year entitled: “Preclinical Development to Patient Perspectives: The Continued Evolution of Nuclear Medicine”, which takes place on Friday 13 May from 9:00 am – 2:30 pm (AEST).
We will also be presenting a poster with our strategic partner GenesisCare on the ProstACT TARGET study.
Finally, Telix Scientific Advisory Board member, Professor Dr. Frederik Giesel will be delivering a keynote presentation entitled: “FAP-ligand: new perspective in cancer staging and theranostics.”
Come and meet with us in person at booth #29-32 to learn about Telix’s imaging agent, Illuccix, and our broad clinical research pipeline focused on targeted radiation for prostate and kidney cancers, glioblastoma and rare diseases.
There is still time to register for the ANZSNM Annual Scientific Meeting here.
To view the Pre-Conference Symposium program please click here.
To view the Conference program please click here.
To return to the Telix homepage please click here.
More Articles
Corporate Spotlight
Telix at ANZSNM Annual Scientific Meeting 2022
9 May 2022 – Corporate Spotlight | Telix supporting and participating in Australian and New Zealand Society of Nuclear Medicine...
ASX News
First Patient Dosed in Phase II Renal Cancer Theranostics Study
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 5 May 2022. Telix announces that a first patient has been dosed in...
ASX News
Telix Further Strengthens European Distribution Network for Illuccix
Melbourne (Australia) and Liège (Belgium)– 22 April 2022. Telix announces agreements with Avanço and THP for the distribution of Telix’s...